Tovecimig COMPANION‑002 secondary topline data set for release; CMPX rises

Compass Therapeutics said it will review topline secondary endpoints from the randomized Phase 2/3 COMPANION‑002 study of tovecimig (a DLL4 x VEGF‑A bispecific antibody) combined with paclitaxel in patients with advanced biliary tract cancer (BTC) during a webcast scheduled for April 27, 2026 at 8:00 a.m. ET. The announcement follows prior topline reporting that the trial met its primary efficacy endpoint.

According to company releases, secondary endpoints to be highlighted include progression‑free survival (PFS), overall survival (OS), duration of response and safety/tolerability measures; the firm previously noted analyses of PFS and OS were on track for the April timeframe and that complete data would be presented at a medical meeting in H1 2026. These details will be closely watched by clinicians and investors because they bear on regulatory and commercial prospects.

The news moved markets: Compass’s Nasdaq‑listed shares (CMPX) recorded a notable after‑hours uptick following the April 24 release, reflecting investor focus on the upcoming data readout and the potential implications for the company’s development pathway. Market participants highlight that PFS/OS outcomes typically carry greater weight for labeling and reimbursement discussions than response‑rate signals alone.

In the broader clinical context, biliary tract cancer remains an area of high unmet need with limited second‑line options; a bispecific approach that targets both DLL4 (Notch pathway) and VEGF‑A aims to disrupt tumor angiogenesis and stem‑cell related pathways, which could complement cytotoxic chemotherapy. Earlier phase results showed signs of activity that prompted the randomized COMPANION‑002 design.

Analysts caution that while positive secondary outcomes could be transformational—supporting regulatory discussions and commercial value—ambiguous or negative PFS/OS results would likely trigger a rapid market re‑pricing. Investors and clinicians will look for detailed subgroup analyses, safety profiles and statistical robustness when the company releases the topline secondary endpoint data and the subsequent full dataset.